Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease (Q50506495)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 1, 1997

Language	Label	Description	Also known as
English	Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease	scientific article published on December 1, 1997

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/9496389

Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/9496389

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

R. E. van Rijswijk

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9496389

11 December 2024

K. Hoekman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9496389

11 December 2024

C. W. Burger

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9496389

11 December 2024

R. H. Verheijen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9496389

11 December 2024

J. B. Vermorken

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9496389

11 December 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9496389

11 December 2024

publication date

1 December 1997

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/9496389

December 1997

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9496389

11 December 2024

full work available at URL

https://academic.oup.com/annonc/article-pdf/8/12/1235/19480504/8-12-1235.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9496389

11 December 2024

https://api.elsevier.com/content/article/PII:S0923753419640664?httpAccept=text/xml

1 reference

10.1023/A:1008296202198

https://api.crossref.org/works/10.1023/A:1008296202198

11 December 2024

https://api.elsevier.com/content/article/PII:S0923753419640664?httpAccept=text/plain

1 reference

10.1023/A:1008296202198

https://api.crossref.org/works/10.1023/A:1008296202198

11 December 2024

http://academic.oup.com/annonc/article-pdf/8/12/1235/19480504/8-12-1235.pdf

Portable Document Format

1 reference

10.1023/A:1008296202198

https://api.crossref.org/works/10.1023/A:1008296202198

11 December 2024

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/9496389

8

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/9496389

12

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/9496389

1235-1241

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/9496389

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cisplatin in hypertonic saline in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraperitoneal cisplatin with systemic thiosulfate protection

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperativ

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

VP-16 and cisplatin as first-line therapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Etoposide salvage therapy for refractory germ cell tumors: an update

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral etoposide is active against platinum-resistant epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Delayed erosion of intraperitoneal chemotherapy catheters into the bowel. Report of two cases

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Secondary cytoreduction for ovarian cancer following cisplatin therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraperitoneal salvage chemotherapy in ovarian cancer: Who is left to treat?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008296202198

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status

7

1 reference

10.1023/A:1008296202198

https://api.crossref.org/works/10.1023/A:1008296202198

11 December 2024

Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission

24

1 reference

10.1023/A:1008296202198

https://api.crossref.org/works/10.1023/A:1008296202198

11 December 2024

Intraperitoneal chemotherapy: technical experience at five institutions

29

1 reference

10.1023/A:1008296202198

https://api.crossref.org/works/10.1023/A:1008296202198

11 December 2024

Anatomic changes in the abdominal cavity during intraperitoneal chemotherapy: prospective study using scintigraphic peritoneography

36

1 reference

10.1023/A:1008296202198

https://api.crossref.org/works/10.1023/A:1008296202198

11 December 2024

Use of intraperitoneal chemotherapy for treatment of ovarian cancer

37

1 reference

10.1023/A:1008296202198

https://api.crossref.org/works/10.1023/A:1008296202198

11 December 2024

Identifiers

10.1023/A:1008296202198

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/9496389

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/9496389

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50506495&oldid=2286191184"